Anti-Hu CD23 Purified

Anti-Hu CD23 Purified
Regulatory status
RUO
Antigen
CD23
Clone
EBVCS-5
Format
Purified
Reactivity
Human
Application
IP, FC (QC tested)
Variant
0.1 mg
11-689-C100
In stock

0.025 mg
11-689-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody EBVCS-5 recognizes an extracellular epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites.
Application
IP, FC (QC tested)
Reactivity
Human
Immunogen
EBV-transformed human cells
Other names
FcεRII, FCER2, Low affinity immunoglobulin epsilon Fc receptor, Lymphocyte IgE receptor, Fc-epsilon-RII, BLAST-2, FCE2, CLEC4J, IGEBF
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
11-689 FC
Flow cytometry analysis (surface staining) of human peripheral blood cells with anti-human CD23 (EBVCS-5) purified, GAM-APC.

Product specific references:

Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55.
PubMed
Rumi C, Rutella S, Leone G, Bonini S: Fc-RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1;91(7):2621-2.
PubMed
Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1991 Dec;86(3):360-6.
PubMed
Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr;8(4):479-90.
PubMed
Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clin Mol Allergy. 2005 May 20;3:6.
PubMed
Variant
0.1 mg
11-689-C100
In stock

0.025 mg
11-689-C025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock